New hope for aggressive uterine cancer: One-Year pill may keep disease at bay

NCT ID NCT06712472

Recruiting now Disease control Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

First seen Jan 21, 2026 · Last updated Jun 19, 2026 · Updated 28 times

Summary

This study tests whether taking a daily targeted therapy pill (olaparib) for one year after standard chemoradiation can prevent endometrial cancer from coming back in patients with a specific genetic change (p53 abnormal). About 554 participants will be randomly assigned to receive olaparib or just observation. The goal is to see if the drug improves how long patients stay cancer-free.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CHU De LIMOGES
RECRUITING

Limoges, 87000, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Centre Antoine LACASSAGNE
RECRUITING

Nice, 06189, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Centre Hospitalier D'Albi
RECRUITING

Albi, 81000, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Centre Hospitalier de Carcassonne
RECRUITING

Carcassonne, 11000, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Centre LEON BERARD
RECRUITING

Lyon, 69008, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Chu Besancon
RECRUITING

Besançon, 25030, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Chu Dijon
RECRUITING

Dijon, 21000, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Clinique Sainte Anne
RECRUITING

Strasbourg, 67000, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Groupe Hospitalier Mutualiste de Grenoble
NOT_YET_RECRUITING

Grenoble, 38000, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Gustave Roussy
RECRUITING

Villejuif, 94805, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Hopital Cochin
NOT_YET_RECRUITING

Paris, 75014, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
INSTITUT CANCEROLOGIE DE L'OUEST-St HERBLAIN
RECRUITING

Saint-Herblain, 44800, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Institut Cancerologie de L'Ouest-Angers
RECRUITING

Angers, 49055, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Institut Marie-Curie
RECRUITING

Paris, 75005, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Institut Paoli Calmettes
RECRUITING

Marseille, 13009, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Olaparib (a targeted therapy pill taken twice daily for one year)

What this could lead to

If successful, this could offer a new maintenance option to delay cancer recurrence in patients with a specific genetic subtype of endometrial cancer.

What could go wrong

This is an early-stage Phase 3 trial; results may not confirm benefit. Olaparib can cause side effects like fatigue, nausea, and blood count changes, and not all patients may tolerate it.

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrial carcinoma endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CANCER ENDOMETRIAL CANCER P53ABN